Dexamethasone News and Research

RSS

Health Secretary urges G20 countries to recognize UK's COVID-19 vaccine clinical trial participants

The rights of vaccine clinical trial volunteers must be safeguarded to help protect everyone against future health crises, Health and Social Care Secretary Sajid Javid will tell G20 health leaders in Rome today (Sunday 5 September).

5 Sep 2021

Rheumatoid arthritis drug plus standard of care may reduce COVID-19 mortality for hospitalized patients

Hospitalized patients with COVID-19 who received the rheumatoid arthritis drug baricitinib, in combination with the standard of care including corticosteroids, died less often than those receiving only the standard of care, according to a study released this week in The Lancet Respiratory Medicine.

1 Sep 2021

Glycyrrhizic acid as a drug candidate for COVID-19

A new study presents the benefits of licorice, an age-old herbal remedy, to treat COVID-19 at all stages.

24 Aug 2021

MHRA approves first monoclonal antibody treatment for COVID-19 in the UK

Following on from a thorough review of the evidence carried out by the MHRA, and recommendation by the Commission on Human Medicines (CHM), the government's independent expert scientific advisory body, the MHRA has approved Ronapreve as the first monoclonal antibody combination product indicated for use in the prevention and treatment of acute COVID-19 infection for the UK.

20 Aug 2021

International collaboration aims to develop better therapy for childhood acute lymphoblastic leukemia

Scientists at St. Jude Children's Research Hospital are working with colleagues in China to develop better therapy for childhood acute lymphoblastic leukemia (ALL).

27 Jul 2021

Research provides new insight into uncontrolled inflammation in COVID-19 patients

Research led by Queen Mary University of London provides new insight into the mechanisms that lead to uncontrolled inflammation in COVID-19 patients.

22 Jul 2021

Could corticosteroids increase mortality in COVID-19 patients without high oxygen supplementation?

A new paper focuses on the role of corticosteroids, in particular, as these were widely used among patients on intensive respiratory support (IRS).

14 Jul 2021

Investigation reveals considerable added benefit of remdesivir for moderately ill COVID-19 patients

Since July 2020, remdesivir has been conditionally approved in Europe for the treatment of coronavirus disease (COVID-19) in adults and adolescents aged 12 years and older with pneumonia who require supplemental oxygen but no invasive ventilation.

6 Jul 2021

Scientists uncover features of T cells that distinguish fatal COVID-19 from non-fatal cases

While vaccines are doing a remarkable job of slowing the COVID-19 pandemic, infected people can still die from severe illness and new medications to treat them have been slow to arise.

1 Jul 2021

How does dexamethasone therapy work in severe COVID-19?

The possible mechanisms that result in dexamethasone being an effective drug against severe SARS-CoV-2 infection are investigated in a new study. The paper’s authors advance the hypothesis that SARS-CoV-2 infection induces cell-specific insensitivity to glucocorticoids, possibly as an unintentional result of the viral replication cycle.

29 Jun 2021

Study finds no evidence for remdesivir's benefit in severe COVID-19 patients

A new analysis of current data indicates that remdesivir does not show efficacy in regulating the severity of the illness.

23 Jun 2021

RedHill presents positive Phase 2 results for oral opaganib in patients with COVID-19 pneumonia

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced presentation of the positive Phase 2 safety and efficacy data for oral opaganib (Yeliva®, ABC294640) in hospitalized patients with COVID-19 pneumonia at the World Microbe Forum (WMF) 2021 (poster #: 5574).

21 Jun 2021

Targeting lung inflammation with cell membrane-based dexamethasone nanodelivery platform

Recently, researchers discuss their development of cell membrane-based nanoparticles that successfully delivered dexamethasone directly to inflamed lung cells.

21 Jun 2021

Cinnamon compound could be useful supplement to dexamethasone in COVID-19 treatment

Researchers in Germany and the United States have conducted a study showing that supplementing dexamethasone treatment with Ceylon cinnamon in cases of coronavirus disease 2019 (COVID-19) may allow dexamethasone to be administered at lower doses, thereby avoiding the side effects that occur with high doses of the steroid.

17 Jun 2021

Immune cell-mimicking nanoparticles deliver drugs directly to inflamed lungs

Nanoengineers at the University of California San Diego have developed immune cell-mimicking nanoparticles that target inflammation in the lungs and deliver drugs directly where they're needed. As a proof of concept, the researchers filled the nanoparticles with the drug dexamethasone and administered them to mice with inflamed lung tissue.

17 Jun 2021

New computational topology strategy to identify existing medicines for treating COVID-19

Researchers from the ESI International Chair of the CEU Cardenal Herrera University (CEU UCH) and ESI Group have just published in scientific journal Pharmaceutics a new computational topology strategy to identify existing medicines that could be applied to treat COVID-19 without waiting for the research and clinical trial phases required to develop a new medicine.

16 Jun 2021

ACT Accelerator partnership welcomes commitment of 870 million vaccine doses, highlights funding gaps

At the close of this year’s G7 Leaders’ summit, the Prime Minister of the United Kingdom of Great Britain and Northern Ireland announced a donation of an additional 870 million vaccine doses from attendees, with the majority to be delivered through COVAX, the vaccines pillar of the Access to COVID 19 Tools Accelerator, within the next year.

15 Jun 2021

SARS-CoV-2 B.1.1.345 variant carrying E484K mutation detected in New York

The report, published in the journal Clinical Infectious Diseases, revealed that the variant detected has been spreading at an alarming rate since November. By February 2021, it accounted for 12.3 percent of all cases in the area.

8 Jun 2021

Researchers identify a novel host-directed therapeutic approach to COVID-19

Researchers in the UK have demonstrated the potential of modulating the expression of angiotensin-converting enzyme 2 (ACE2) as a novel host-directed therapeutic approach to protecting against coronavirus disease 2019 (COVID-19).